A Study of PYX-201 in Advanced Solid Tumors (NCT05720117)
A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants With Advanced Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with recurrent/metastatic (R/M) solid tumors, and to determine the objective response rate (ORR) in participants treated with PYX-201 as a single agent.
Who can join: Review the eligibility criteria below.
Location: HonorHealth Research Institute — Scottsdale, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (29 Sites)
Showing the first 25 of 29 sites.
- HonorHealth Research Institute — Scottsdale, Arizona
- Ronald Reagan UCLA Medical Center — Los Angeles, California
- SCRI - HealthOne Denver — Denver, Colorado
- SCRI - Florida Cancer Specialists — Sarasota, Florida
- Winship Cancer Institute, Emory University — Atlanta, Georgia
- University of Chicago Medicine — Chicago, Illinois
- Massachusetts General Hospital — Boston, Massachusetts
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Washington University School of Medicine — St Louis, Missouri
- Memorial Sloan Kettering Cancer Center — New York, New York
- University of Cincinnati Medical Center — Cincinnati, Ohio
- University of Pennsylvania, Abramson Cancer Center — Philadelphia, Pennsylvania
- Rhode Island Hospital — Providence, Rhode Island
- NEXT Dallas — Dallas, Texas
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- NEXT San Antonio — San Antonio, Texas
- NEXT Virginia — Fairfax, Virginia
- Institut Jules Bordet — Brussels, Brussels Capital
- Cliniques Universitaires Saint-Luc — Brussels, Brussels Capital
- Universitair Ziekenhuis Antwerpen — Edegem, Edegem
- Universitair Ziekenhuis Gent — Ghent, Gent
- Hospital Universitari Vall d'Hebrón — Barcelona, Barcelona
- START Madrid - Hospital Universitario Fundación Jiménez Díaz — Madrid, Madrid
- Hospital Universitario 12 de Octubre — Madrid, Madrid
- Hospital Universitario HM Sanchinarro — Madrid, Madrid
📞 Contact the Study Coordinator
Phone: (339) 545-8252
Email: clinicaltrials@pyxisoncology.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumor
- A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors — Houston, Texas
- A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer — Middletown, New Jersey
- A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer — Basking Ridge, New Jersey
- Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors — Chicago, Illinois
- A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors — New York, New York
- Concurrent Azeliragon With Craniospinal Irradiation — New York, New York
Explore by condition: All Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.